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Disorders/differences of sex development (DSD) are the result of a discordance between 
chromosomal, gonadal, and genital sex. DSD may be due to mutations in any of the genes 
involved in sex determination and development in general, as well as gonadal and/or genital 
development specifically. MAMLD1 is one of the recognized DSD genes. However, its role is 
controversial as some MAMLD1 variants are present in normal individuals, several MAMLD1 
mutations have wild-type activity in functional studies, and the Mamld1-knockout male mouse 
presents with normal genitalia and reproduction. We previously tested nine MAMLD1 variants 
detected in nine 46,XY DSD patients with broad phenotypes for their functional activity, but 
none of the mutants, except truncated L210X, had diminished transcriptional activity on known 
target promoters CYP17A1 and HES3. In addition, protein expression of MAMLD1 variants was 
similar to wild-type, except for the truncated L210X. We hypothesized that MAMLD1 variants 
may not be sufficient to explain the phenotype in 46,XY DSD individuals, and that further genetic 
studies should be performed to search for additional hits explaining the broad phenotypes. We 
therefore performed whole exome sequencing (WES) in seven of these 46,XY patients with 
DSD and in one 46,XX patient with ovarian insufficiency, who all carried MAMLD1 variants. 
WES data were filtered by an algorithm including disease-tailored lists of MAMLD1-related and 
DSD-related genes. Fifty-five potentially deleterious variants in 41 genes were identified; 16/55 
variants were reported in genes in association with hypospadias, 8/55 with cryptorchidism, 
5/55 with micropenis, and 13/55 were described in relation with female sex development. 
Patients carried 1-16 variants in 1-16 genes together with their MAMLD1 variation. Network 
analysis of the identified genes revealed that 23 genes presented gene/protein interactions with 
MAMLD1. Thus, our study shows that the broad phenotypes of individual DSD might involve 
multiple genetic variations contributing towards the complex network of sexual development.
Keywords: whole exome sequencing, MAMLD1, disorders/differences of sex development, hypospadias, 
phenotype variability, oligogenic disorder
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INTRODUCTION
Disorders/differences of sex development (DSD) occur when 
there is a discordance between chromosomal, gonadal, and 
genital sex (Ostrer, 2014). DSD may be due to mutations in any 
of the genes involved in sex determination and development 
in general, as well as gonadal and/or genital development 
specifically (Ostrer, 2014).
MAMLD1 (Xq28, OMIM 300120) is one of the recognized 
DSD-related genes (Fukami et al., 2006; Baxter et al., 2015). 
Variations in MAMLD1 sequence have been described mainly 
in 46,XY DSD individuals, mostly associated with hypospadias 
(Fukami et al., 2006; Kalfa et al., 2008; Chen et al., 2010; Kalfa 
et al., 2012; Metwalley and Farghaly, 2012; Camats et al., 2015; 
Igarashi et al., 2015; Eggers et al., 2016), but also with other 
DSD phenotypes, including micropenis (Chen et al., 2010; 
Kalfa et al., 2012; Camats et al., 2015; Liu et al., 2017), and/
or crypthorchidism (Fukami et al., 2006; Kalfa et al., 2008; 
Kalfa et al., 2012; Camats et al., 2015), 46,XY with female 
external genitalia (Fukami et al., 2006; Camats et al., 2015) 
and 46,XY with complete gonadal dysgenesis (Ruiz-Arana et 
al., 2015). Furthermore, one homozygous MAMLD1 variant 
was also reported in a 46,XX patient with gonadal dysgenesis, 
primary amenorrhea, bilateral streak gonads and clitoromegaly 
(Brandao et al., 2011).
However, the role of MAMLD1 in sex development is 
controversial for several reasons: a) some MAMLD1 variants 
are present in the normal population (Fukami et al., 2006; Chen 
et al., 2010; Gaspari et al., 2011; Kalfa et al., 2011); b) the same 
MAMLD1 variant may be present in patients with different 
phenotypes (Camats et al., 2015); c) MAMLD1 variants are 
not present in all DSD individuals of the same family (Fukami 
et al., 2006); d) several MAMLD1 mutations present wild-type 
activity in functional studies (Camats et al., 2015); and e) the 
Mamld1-knockout male mouse presents with normal genitalia 
and reproduction (Miyado et al., 2012; Miyado et al., 2017).
MAMLD1 is expressed in human fetal and adult testis and in 
human ovaries (Fukami et al., 2006; O’Shaughnessy et al., 2007; 
Camats et al., 2015), and seems to be involved in sex development 
in fetal life and in adult reproductive function. Yet its exact role 
is not clear. It is expressed in mice gonadal cells during start of 
androgen biosynthesis up to male external genitalia formation 
and is therefore thought to be involved in the expression of 
Leydig-cell genes (Miyado et al., 2012), as well as supporting 
testosterone production in critical periods of male development 
(Fukami et al., 2008; Nakamura et al., 2011). In contrast, 
Mamld1-KO mice present normal external genitalia (but small 
testes and reduced seminiferous tubule size and proliferating 
germ cells) and reproduce similarly to wild-type mice (Miyado 
et al., 2012; Miyado et al., 2017). These findings challenge the role 
of MAMLD1 in sex development.
In a previous study, we tested functional activity of nine 
MAMLD1 variants detected in nine 46,XY DSD patients with 
broad phenotypes (Camats et al., 2015). None of the MAMLD1 
mutants, except truncated L210X, had diminished transcriptional 
activity on known target promoters CYP17A1 and HES3. In 
addition, protein expression of MAMLD1 variants was similar 
to wild-type, except for the truncated L210X. We therefore 
hypothesized that MAMLD1 variants may not be sufficient to 
explain the phenotype in 46,XY DSD carriers, and that further 
genetic studies should be performed to search for additional hits 
explaining the broad variability.
In the past decade, High throughput sequencing (HTS) 
has changed the genetic approach in research and diagnostics. 
Whole-exome sequencing (WES) has led to the discovery of many 
new genes and has given insight into complex traits. Oligogenic 
inheritance is currently discovered for several disorders by 
HTS. In the field of sex development, digenic inheritance has 
recently been suggested in a 46,XY DSD patient with gonadal 
dysgenesis (NR5A1 and MAP3K1 variants) (Mazen et al., 2016); 
in a family with 46,XY DSD males (NR5A1 variants) and 46,XX 
POF females (NR5A1 and TBX2) (Werner et al., 2017); as well 
as in a DSD patient with ambiguous genitalia, micropenis, 
and inguinal testes (SEMA3A and AKR1C4) (Fan et al., 2017). 
Similarly, we found oligogenic origin of disease in heterozygous 
NR5A1 46,XY DSD patients by performing WES (Camats et al., 
2018). In addition, in patients with hypospadias, an oligogenic 
origin was suggested by two other NGS studies (Kon et al., 2015; 
Eggers et al., 2016).
Therefore, in this study, we performed WES in seven 46,XY 
patients with DSD (Camats et al., 2015) and one 46,XX patient 
with ovarian insufficiency, who all carried MAMLD1 variants. 
WES data were filtered by common tools and a disease-tailored 
algorithm including MAMLD1-related and DSD-related 
known and candidate genes. Additional hits in likely disease-
causing genes were detected in all eight MAMLD1 carriers. Our 
results suggest that oligogenic origin of disease may contribute 
towards the broad phenotypes of human MAMLD1.
PATIENTS AND METHODS
Patients
The study was approved by the Ethics Committee of Hospital 
Universitari Vall d'Hebron (Barcelona, Spain) (CEIC: 
PR(IR)23/2016). Written informed consent was obtained 
from the patients for the publication of their cases. Eight 
DSD patients (seven 46,XY and one 46,XX) each carrying 
one MAMLD1 variant were analyzed using WES. Clinical 
and genetic characteristics of 46,XY patients were previously 
reported in detail in Camats et al., (2015) and are summarized 
in Table 1 together with the 46,XX  patient.
DNA Extraction, WES and Bioinformatic 
Analysis
DNA was extracted from blood leukocytes using QiaCube 
(Qiagen, Hilden, Germany) or manually using a DNA isolation 
kit (Qiagen). WES was performed by CNAG (Centre Nacional 
d’Anàlisi Genòmica, Barcelona, Spain). Libraries were prepared 
with a SureSelect Human All Exon V5 capture kit (Agilent, Santa 
Clara, CA, USA) and sequenced with a HiSeq™ 2000 sequencing 
system (v3, 2x100, Illumina, San Diego, CA, USA). Putative 
candidate variants were confirmed by Sanger sequencing.
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TABLE 1 | Clinical, biochemical and genetic characteristics of the studied MAMLD1 patients. 
Patient Karyotype
assigned sex
Phenotype and origin Gonadal function 
(age)
Adrenal function 
(age)
MAMLD1 variant Variants after 
filtering by 
gene list (A)
Candidate 
variants 
(B)
Candidate 
genes (C)
1
(7)
46,XY
Female
Penoscrotal hypospadias.
Small penis.
Unilateral cryptorchidia.
Histology: normal for age (2y).
Venezuelan origin.
Normal hCG test. Normal Synacthen test. p.V505A NM_005491:c.1514T>C 547 9 7
2
(6)
46,XY
Male
Penoscrotal hypospadias.
Small penis.
Testes: 2 ml.
Spanish origin.
Normal baseline T (3m).
Normal hCG test (9m).
Normal baseline
(3d).
p.A503E NM_005491:c.1508C>A 492 1 1
3
(9)
46,XY
Female
Penoscrotal hypospadias.
Small penis.
Histology: normal for age (nests of normal 
Leydig cells; normal fertility index (1y)
Müllerian ducts.
Spanish origin
Normal baseline (12m).
No hCG test.
NA p.S730S NM_005491:c.2190G>A 570 2 2
4
(3)
46,XY
Female
Female genitalia.
Gonads in labia.
Spanish origin.
Normal hCG test (2y). Normal baseline
(2y).
p.H347Q NM_005491:c.1041C>A
rs62641609
633 4 4
5
(4)
46,XY
Male
Penoscrotal hypospadias.
Testes 2 ml.
Spanish origin.
Normal hCG test.
Normal AMH (2.5y).
Normal baseline
(2.5y).
p.H347Q NM_005491:c.1041C>A
rs62641609
929 6 6
6
(8)
46,XY
Male
Penoscrotal hypospadias.
Small penis.
Testes 1 ml.
Esophageal atresia.
Right aortic arch.
North African origin.
Normal prepubertal 
baseline T (15 m).
Normal AMH. 
Normal baseline
(15 m).
p.L724V NM_005491:c.2170C>G 710 16 16
7
(5)
46,XY
Male
Hypospadias.
Short penis.
Testes 8 ml.
Delayed puberty.
Gynaecomastia.
Fathered a boy.
Swiss origin.
Normal baseline
T and gonadotropins 
(70y).
Fathered a boy.
Normal baseline
(70y).
p.Q501Q502 
NM_005491:c.1503_1504dupCAGCAG
429 5 5
8 46,XX
Female
Female external genitalia.
Small ovaries and uterus, with fallopian 
tubes. Primary amenorrhea (15y).
Histology: large amount of primordial 
follicles (no evidence of maturation), atresic 
follicles.
Delayed growth.
Spanish origin.
High gonadotropins 
and low/normal 
estradiol (27y).
Normal (27y). NM_005491:c.*126C>MIT 574 14 13
All patients presented one hemizygous/heterozygous variant in MAMLD1. In parentheses: patients in Camats et al. (2015); NA, not analyzed; d, day(s); m, month(s); y, year(s). (A) Filtered by DSD-related and MAMLD1-related gene 
list. (B) Number of candidate variants per patient: related to sex development, DSD phenotypes, and/or in MAMLD1-related genes, and with MAF ≤ 0.01. (C) Number of candidate genes per patient: genes containing at least one 
candidate variant per patient.
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The genomic datasets were annotated (alignment with human 
genome hg19/grch37) and filtered with the functional annotation 
of genetic variants from HTS data (ANNOVAR; http://annovar.
openbioinformatics.org/) (Wang et al., 2010), visualized and 
explored in Integrative Genomics Viewer (IGV, Broad Institute, 
Cambridge, MA, USA; https://www.broadinstitute.org/igv/ 
(Robinson et al., 2011). Frequencies of variants of relevant 
candidate genes were obtained from the Genome Aggregation 
Database (gnomAD; http://gnomad.broadinstitute.org/about) 
(Lek et al., 2016) and the Collaborative Spanish Variant Server 
(CSVS; CIBERER BIER, Valencia, Spain; http://csvs.babelomics.
org/; August 2018) (Dopazo et al., 2016). gnomAD includes 
gene variants from exome and genome sequencing data: 123,136 
exomes and 15,496 genomes from unrelated individuals (from 
population and disease-specific studies). CSVS database includes 
(among others) exomes from a population of 267 healthy 
unrelated subjects.
WES data were filtered by a disease-tailored list of MAMLD1-
related and DSD-related known and candidate genes (n = 606) 
similar to the algorithm previously set up for Camats  et  al., 
(2018). We generated a project-specific filter for DSD-related 
and MAMLD1-related genes by searching in published literature 
and databases. DSD-related genes are part of our DSD-gene 
database and tools (Camats et al., 2018), which have been 
currently updated. The DSD-related gene list included genes 
with reported (potentially) deleterious variants in patients 
with 46,XY and 46,XX DSD, genes with reported (potentially) 
disease-causing variants in syndromic patients with involvement 
of sex development, those “related” to DSD conditions in KO/
mutant animal models (mice and rats), and also overexpressed, 
upregulated or downregulated genes in rodent embryonic 
gonadal cells (Camats et al., 2018). For the search for functional 
human partners of MAMLD1 and for possible interactions within 
interesting genes, the Search Tool for the Retrieval of Interacting 
Genes/Proteins (STRING, http://string-db.org/) (Jensen et al., 
2009) and the Biological General Repository for Interaction 
Datasets (BioGRID, thebiogrid.org) (Stark, 2006) were used.
We used 30 pathogenic predictors to predict possible impact 
of amino acid substitutions on the structure, function and 
evolutionary conservation of corresponding human proteins 
and to predict impact on splicing. These in-silico predictors were 
accessed through ANNOVAR (Wang et al., 2010) annotation 
and run through Alamut Visual 2.11 (https://www.interactive-
biosoftware.com/es/alamut-visual/). Functional exonic predictors 
were CADD (Combined Annotation Dependent Depletion 
of single-nucleotide and insertion/deletion variants, http://
cadd.gs.washington.edu/) (Kircher et al., 2014), SIFT (Scale-
invariant feature transform; http://sift.jcvi.org/), PolyPhen-2 
(Polymorphism Phenotyping v2: HumDiv, HumVar; http://
genetics.bwh.harvard.edu/pph2/index.shtml), Provean (http://
provean.jcvi.org), MutationAssessor (http://mutationassessor.
org/r3/), Mutation Taster (http://www.mutationtaster.org/), LRT, 
FATHEMM, Fathmm-MKL, PROVEAN, VEST3 (Variant Effect 
Scoring Tool), MetaSVM, MetaLR, MCAP, DANN and fitCons. 
Exonic predictors on evolutionary conservation were: GERP++, 
phyloP (vertebrate and mammalians), phastCons (vertebrate 
and mammalians) and SiPhy. Splicing predictors were: splicing 
predictors from dbscSNV ADA and RF and SPIDEX splicing 
predictor (DPSI), and those splicing predictors from Alamut 
Visual software were: SSF, MaxEnt, NNSPLICE, GeneSplicer 
and Ex-Skip.
The following bioinformatics software tools were used for 
the interpretation and classification of variants: InterVar (http://
wintervar.wglab.org/, clinical interpretation of genetic variants 
by the ACMG/AMP 2015 guideline), VarSome (The Human 
Genomics Search Engine; https://varsome.com/), ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/) and Alamut Visual 2.11 
(https://www.interactive-biosoftware.com/es/alamut-visual/). 
We searched for reported (potentially) disease-causing variants 
with the Human Gene Mutation Database (HGMD® Professional 
2018.2, http://www.biobase-international.com/product/hgmd; 
Biobase) and dbSNP (http://www.ncbi.nlm.nih.gov/snp/). We 
used STRING for the search for interactions within genes carriers 
of interesting variants (DSD-related and/or MAMLD1-related). 
Data from STRING are extracted from known interactions 
(curated databases, experimentally determined interactions), 
predicted interactions (gene neighborhood, gene fusions, 
gene co-occurrence) and other inferred evidences such as text 
mining, co-expression and protein homology. We used Pubmed 
(https://www.ncbi.nlm.nih.gov/pubmed/) and OMIM (https://
www.omim.org) to build our DSD gene list and for further 
data analysis. The datasets generated for this study are publicy 
available in dbSNP (Sherry, 2001): https://www.ncbi.nlm.nih.
gov/projects/SNP/snp_viewBatch.cgi?sbid=1063030.
Variant Analysis Per Patient
After annotation, variant analysis was performed by the 
following steps. A) Each patient’s WES data were first filtered by 
our MAMLD1- and DSD-related known and candidate genes. 
B) We kept variants with MAF (minor allele frequency) ≤0.015 
or not detected in gnomAD, and variants with the following 
predicted type, consequences and locations: splicing (intronic 
or exonic), exonic, intergenic, regulatory. C) We confirmed the 
correct annotation and location of variants by checking their 
alignment data in IGV (alignment with human genome hg19/
grch37) (data not shown). D) We excluded variants that were 
considered non-relevant for our study: E.g. 1) variants found in 
more than two patients, 2) variants in repeat regions, 3) variants 
in genes or gene regions with high variability, 4) variants with low 
coverage and/or low quality, 5) variants with non-similar allelic 
depths. E) We revised variants with the annotated pathogenic 
predictors: functional exonic, evolutionary-conservation and 
splicing predictors (ANNOVAR and Alamut Visual software), as 
previously described. F) We run InterVar and VarSome to classify 
the variants, searched for reported (potentially) human disease-
causing variants with the HGMD, and revised evidences of 
relationship with DSD, sex development and clinical phenotype 
of each patient with literature and database search. G) We 
used STRING to find out interactions among genes carriers of 
interesting variants (DSD-related and/or MAMLD1-related) 
(Figures 1 and 2). H) We checked MAF in a healthy cohort of 
Spanish population (CSVS: 267 unrelated healthy controls). 
I) We rejected variants with MAF ≥ 0.01 (gnomAD, CVSV, 
Oligogenic MAMLD1 DSD PhenotypesFlück et al.
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August 2018), thus less plausible to be a DSD-causing variant. 
Importantly, synonymous variants were not rejected because it 
has been shown that they may affect splicing.
RESULTS
WES performed in eight unrelated subjects (seven 46,XY and 
one 46,XX) harboring hemizygous/heterozygous MAMDL1 
variants revealed several candidate gene variants that potentially 
contribute to each patient’s phenotype. A detailed summary 
of patients’ characteristics and number of variants and genes 
is shown in Table 1. A list of identified candidate variants and 
corresponding information from literature is given in Table 2.
We identified a total of 55 potentially deleterious/candidate 
heterozygous/hemizygous variants in 41 genes in the eight 
hemizygous/heterozygous MAMLD1 patients (Tables 1 and 2). 
In the seven 46,XY patients 1–16 variants were found in a total 
of 1–16 genes, while the 46,XX MAMLD1 patient revealed 14 
additional variants in 13 genes. (Tables 1 and 2).
Patient 1 harbored nine variants in seven genes: CYP1A1, 
EVC, GRID1, NOTCH1, RET, RIPK4 and ZBTB16, all of them 
associated to gonadal/genital anomalies (Table 2). Patient 2 
carried one variant in RECQL4, associated with syndromic 
hypospadias (Table 2). Patient 3 presented two variants in two 
genes: GLI2 (associated to gonadal/genital anomalies) and 
RECQL4 (associated to syndromic hypospadias) (Table 2). 
Patient 4 had four variants in four genes: CDH23, COL9A3, 
MAML1 and NOTCH1; all, except MAML1, have been proposed 
to be associated with gonadal development (Table 2). In patient 
5, six variants in six genes were found: BNC2, FGF10, HSD3B2, 
IRX5, MAML2 and NOTCH2; all, except MAML2, have also been 
associated with hypospadias or gonadal development (Table 2). 
Patient 6 carried 16 variants in 16 genes: ATF3, BNC2, CYP1A1, 
EYA1, FLNA, FRAS1, GLI3, HOXA13, IRX5, IRX6, MAML1, 
NRP1, MAML3, PROP1, PTPN11 and WDR11 (Table 2). Thirteen 
of these genes are associated with risk of hypospadias and/or 
syndromes that include abnormal gonadal/genital development, 
whereas MAML1 is unrelated, MAML3 has been proposed to 
be associated with female gonadal development and PROP1 
has only been associated with anterior pituitary insufficiency/
hypogonadotropic hypogonadism. In addition, six of these genes 
have previously been described in patients with aortic diseases 
and cardiopathies (Table 2). Patient 7 presented five variants in 
five genes: EVC, MAML3, NOTCH2, PPARGC1B and WDR11; 
four of them associated with hypospadias or male gonadal 
development and one, MAML3, with female gonadal development 
(Table 2). Finally, patient 8 harbored 14 variants in 13 genes: 
CUL4B, DAPK1, EMX2, FREM2, IGFBP2, MAML2, MAML3, 
MYO7A, NOTCH1, PIK3R3, TGFBI, WNT9A and WNT9B. 
FIGURE 1 | Interaction network of DSD- and MAMLD1-related genes identified in DSD individuals harboring genetic variants in MAMLD1. The scheme depicts an 
overview of detected genes and their interrelationship. For the search for functional human partners, the Search Tool for the Retrieval of Interacting Genes/Proteins 
(STRING, http://string-db.org/) was used. Nodes represent proteins. Filled nodes show proteins with known or predicted 3D structure. Empty nodes depict proteins 
with unknown 3D structure. Candidate genes are underlined. Known interactions correspond to curated databases (turquoise lines) and experimentally determined 
interactions (pink lines). Predicted interactions correspond to gene neighborhood (green lines), gene fusions (red lines) and gene co-occurrence (blue lines). Other 
interactions correspond to text mining (yellow lines), co-expression (black lines) and protein homology (violet lines).
Oligogenic MAMLD1 DSD PhenotypesFlück et al.
6 August 2019 | Volume 10 | Article 746Frontiers in Genetics | www.frontiersin.org
FIGURE 2 | Interaction networks of DSD- and MAMLD1-related genes identified per single MAMLD1 individual. (A) to (F) correspond to the interaction networks 
per patient. For the search for functional human partner, the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, http://string-db.org/) was used. 
Nodes represent proteins. Filled nodes show proteins with known or predicted 3D structure. Empty nodes depict proteins with unknown 3D structure. Candidate 
genes are underlined. Known interactions correspond to curated databases (turquoise lines) and experimentally determined interactions (pink lines). Predicted 
interactions correspond to gene neighborhood (green lines), gene fusions (red lines) and gene co-occurrence (blue lines). Other interactions correspond to text 
mining (yellow lines), co-expression (black lines) and protein homology (violet lines). Genes with no interactions are on the right side of each network.
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TABLE 2 | Identified genes and variants per patient after specific filtering.
Patient Gene Chromosome: 
Coordinates
Type/
consequence
HGVSc,HGVSp dbSNP ID gnomAD: 
MAF
CSVS: 
MAF
Predictors Interpretation/classification (6) Evidence
Exonic 
predictor: 
CADD (1)
Exonic 
predictors: 
Functional 
impact (2)
Exonic 
predictors: 
conservation 
(3)
Splicing 
predictor 
(4)
Splicing 
predictors 
(Alamut) 
(5)
InterVar ClinVar VarSome ACMG HGMD: 
variant (7)
Gene characteristics: 
evidences for genotype-
phenotype correlation (8)
1 CYP1A1 15:75013544 snv/missense NM_000499.5:c.1162C>G:p.
(His388Asp)
– ND ND 24.9 13 6 0 5 VUS ND – VUS: PM2, 
PP3
No Association to hypospadias 
(van der Zanden et al., 
2012)
1 EVC 4:5798754 snv/missense NM_153717.2:c.1892C>T:p.
(Thr631Met)
rs139481521 0.0003 ND 23.5 5 3 0 3 VUS VUS – VUS: BP4 No Syndromic (Ellis–van 
Creveld syndrome) 
micropenis (D’Asdia et al., 
2013; Ibarra-Ramirez 
et al., 2017), gonadal 
development? (Beverdam 
and Koopman, 2006; 
Jameson et al., 2012)
1 EVC 4:5785368 snv/
synonymous
NM_153717.2:c.1653G>A:p.
(Pro551=)
rs151293705 0.0003 ND 2.382 NA NA 1 3 Likely 
benign
other VUS VUS: BP7 No Syndromic (Ellis–van 
Creveld syndrome) 
micropenis (D’Asdia et al., 
2013; Ibarra-Ramirez 
et al., 2017), gonadal 
development? (Beverdam 
and Koopman, 2006; 
Jameson et al., 2012)
1 GRID1 10:87966142 snv/missense NM_017551.2:c.499A>G:p.
(Met167Val)
rs956188880 0.00004 ND 10.04 1 5 0 NA VUS ND – VUS: BP4 No Candidate to hypospadias 
(van der Zanden et al., 
2012)
1 NOTCH1 9:139399213 snv/
synonymous
NM_017617.5:c.4930C>T:p.
(Leu1644=)
rs568700183 0.0003 ND 0.018 NA NA 0 4 Likely 
benign
Likely 
benign|Likely 
benign
Likely 
benign
Likely benign: 
BP6, BP7
No Related to SHH and FGF10 
(Grinspon and Rey, 2014)
1 RET 10:43609955 snv/missense NM_020975.5:c.1907C>T:p.
(Thr636Met)
rs1035958105 0.00001 0 23.0 6 6 0 NA VUS VUS VUS Likely 
pathogenic: 
PM1, PM2, 
PP2, PP3
DM; thyroid 
carcinoma
Syndromic (CAKUT 
syndrome) cryptorchidism 
(Chatterjee et al., 2012), 
gonadal development? 
(Jameson et al., 2012; Li 
et al., 2014)
1 RIPK4 21:43161468 snv/missense NM_020639.2:c.1885G>A:p.
(Asp629Asn)
rs199669994 0.00004 ND 7.899 4 4 NA NA VUS ND – VUS: PM2 BP1 No Syndromic (Popliteal 
pterygium syndrome) 
genital hypoplasia (Mitchell 
et al., 2012), micropenis, 
hypoplastic scrotum, 
inguinal hernia (Kalay 
et al., 2012), gonadal 
development? (Beverdam 
and Koopman, 2006; 
Jameson et al., 2012)
1 RIPK4 21:43176830 snv/missense NM_020639.2:c.329C>T:p.
(Ser110Leu)
rs200823657 0.00005 ND 22.7 3 5 0 NA VUS NDw – VUS: PM2 BP1 No Syndromic (Popliteal 
pterygium syndrome) 
genital hypoplasia (Mitchell 
et al., 2012), micropenis, 
hypoplastic scrotum, 
inguinal hernia (Kalay 
et al., 2012), gonadal 
development? (Beverdam 
and Koopman, 2006; 
Jameson et al., 2012)
1 ZBTB16 11:114027160 snv/intronic NM_006006.5:c.1366+4G>C – ND ND 13.81 NA NA 1 4 ND ND – VUS: PM2 BP1 No Syndromic (deletion 
11q23) cryptorchidism and 
micropenis (Fischer et al., 
2008)
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variant (7)
Gene characteristics: 
evidences for genotype-
phenotype correlation (8)
2 RECQL4 8:145738828 snv/missense NM_004260.3:c.2237C>T:(p.
Ala746Val)
rs201883228 0.0002 ND 26.8 6 5 NA NA VUS VUS VUs VUS: BP1 No Syndromic (Rothmund–
Thomson syndrome) 
hypospadias, bilateral 
inguinal hernia (Kellermayer 
et al., 2005) 
3 GLI2 2:121747688 snv/missense NM_005270.4:c.4198G>T:p.
(Gly1400Cys)
rs143914758 0.0001 ND 23.4 7 2 NA NA Likely 
benign
ND VUS VUS: - No Increased risk of 
hypospadias (Carmichael 
et al., 2013), male gonadal 
development (Jameson 
et al., 2012), masculinization 
of male external genitalia 
(Rey et al., 2000)
3 RECQL4 8:145737701 snv,missense NM_004260.3:c.3062G>A:p.
(Arg1021Gln)
rs34666647 0.004 2.375 2 0 0 4 Likely 
benign
other|Benign Benign Likely benign: 
PM2, PM5, 
BP1, BP4
Cancer Syndromic (Rothmund–
Thomson Syndrome) 
hypospadias, bilateral 
inguinal hernia (Kellermayer 
et al., 2005)
4 CDH23 10:73559034 snv/nonsense NM_022124.5:c.7221C>A:p.
(Tyr2407*)
rs779038178 ND 0.002 35 5 6 1 3 Likely 
pathogenic
ND – Pathogenic: 
PVS1, PM2, 
PP3
No Gonadal development? 
(Jameson et al., 2012; Li 
et al., 2014)
4 COL9A3 20:61448956 snv/missense NM_001853.4:c.116C>G:(p.
(Pro39Arg)
rs1028982816 0.00001 ND 22.7 12 5 0 NA VUS ND – VUS: PP3 No Male gonadal development 
(Nef et al., 2005; Beverdam 
and Koopman, 2006; 
Jameson et al., 2012)
4 MAML1 5:179193385 snv/
synonymous
NM_014757.4:c.1374C>T:p.
(Asp458=)
rs61748799 0.003 0.004 0.089 NA NA 0 1 Likely 
benign
ND – VUS: BP7 No No (MAMLD1-related)
4 NOTCH1 9:139401803 snv/
synonymous
NM_017617.5:c.3597C>T:p.
(Leu1199=)
rs150666307 0.00009 ND 11.70 NA NA 0 3 Likely 
benign
Likely benign Likely 
benign
Likely benign: 
BP6, BP7
No Related to SHH and FGF10 
(Grinspon and Rey, 2014)
5 BNC2 9:16436324 snv/missense NM_017637.5:c.1868C>A:p.
(Pro623His)
rs114596065 0.0022 0.002 5.290 8 6 NA NA Benign Benign Benign VUS: BP6 No Hypospadias (Bhoj et al., 
2011; van der Zanden et al., 
2012; Baxter et al., 2015; 
Kon et al., 2015), gonadal 
development? (Jameson 
et al, 2012)
5 FGF10 5:44388817 snv/upstream/
missense
NG_011446.1:c.-33G>A rs17233910 0.005 0.002 19.99 NA NA NA NA ND ND – VUS: - No Increased risk hypospadias 
in human (van der Zanden 
et al., 2012; Carmichael 
et al., 2013; Svechnikov 
et al., 2014); development 
of the glans penis (Rey 
et al., 2000)
5 HSD3B2 1:119964831 snv/missense NM_000198.3:c.707T>C:p.
(Leu236Ser)
rs35887327 0.003788 ND 8.277 3 3 NA NA Likely 
benign
VUS VUS Likely 
Pathogenic: 
PS1, PP2, 
PP5, BP4
DM?; 
HSD3B2 
deficiency
Hypospadias (Codner et al., 
2004; Kon et al., 2015; 
Eggers et al., 2016), sex 
development (Baxter and 
Vilain, 2013; Baxter et al., 
2015), hormone synthesis 
(McCartin et al., 2000)
5 IRX5 16:54967040 snv/missense NM_005853.5:c.707C>T:p.
(Pro236Leu)
rs115549200 0.0088 ND 11.97 3 4 NA NA Benign ND – VUS: BP4 No Association to hypospadias 
(Geller et al., 2014; 
Grinspon and Rey, 
2014), female gonadal 
development? (Nef et al., 
2005)
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5 MAML2 11:95826473 snv/missense NM_032427.3:c.722G>A:p.
(Arg241Gln)
rs111958464 0.005 ND 32 6 6 0 NA VUS ND – VUs: - No No (MAMLD1-related)
5 NOTCH2 1:120469147 snv/
nonsynonymous
NM_024408.3:c.3980A>G:p.
(Asp1327Gly)
rs61752484 0.0037 0.004 20.4 6 6 0 NA Likely 
benign
Benign Benign VUS: BP6 DM?; 
cardiopathy
Primary ovarian failure 
(Patiño et al., 2017); male 
gonadal development? 
(Jameson et al., 2012)
6 ATF3 1:212788544 snv/missense NM_001674.3:c.181G>T:p.
(Ala61Ser)
– ND ND 7.826 3 5 1 NA Benign ND – VUS: PM2, 
BP4
No Hypospadias (Beleza-
Meireles et al., 2008; 
van der Zanden et al., 
2012), female gonadal 
development? (Jameson 
et al., 2012)
6 BNC2 9:16436324 snv/missense NM_017637.5:c.1868C>A:p.
(Pro623His)
rs114596065 0.0022 0.002 5.290 8 6 NA NA Benign Benign Benign VUS: BP6 No Hypospadias (Bhoj et al., 
2011; van der Zanden et al., 
2012; Baxter et al., 2015; 
Kon et al., 2015), gonadal 
development? (Jameson 
et al., 2012)
6 CYP1A1 15:75012979 snv/missense NM_001319216.2:c.1303C> 
A:p.(Arg435Ser)
rs41279188 0.0047 ND 33 11 5 NA NA VUS ND Benign VUS: PP3, BP6 No Association to hypospadias 
(van der Zanden et al., 
2012)
6 EYA1 8:72211882 snv/
synonymous
NM_000503.5:c.630T>C:p.
(Ser210=)
rs373102227 0.00008 ND 10.56 NA NA 1 4 Likely 
benign
VUS VUS VUS: PP3, BP7 No Associated to hypospadias 
(Grinspon and Rey, 2014; 
Hwang et al., 2014), male 
gonadal development? 
(Jameson et al., 2012)
6 FLNA X:153596078 snv/
synonymous
NM_001456.3:c.651C>T:p.
(Asp217=)
rs34644500 0.0002 ND 5.473 NA NA 1 3 Likely 
benign
Likely benign Likely 
benign
Likely benign: 
BP4, BP6, 
BP7
No Hypospadias, 
cryptorchidism, diminished 
androgen receptor (Carrera-
García et al., 2017), female 
gonadal development? 
(Jameson et al., 2012)
6 FRAS1 4:79334181 snv/missense NM_025074.6:c.4367T>C:p.
(Ile1456Thr)
rs560902495 0.00003 ND 24.6 12 5 NA NA VUS ND – VUS: PM2, 
PP3, BP1
No Syndromic (Fraser 
syndrome) abnormal 
genitourinary system 
(Retterer et al., 2016; 
Kornacki et al., 2017); 
female gonadal 
development? (Jameson 
et al., 2012)
6 GLI3 7:42066017 snv/intronic NM_000168.5:c.1029-6G>A rs748670269 0.00002 ND 0.004 NA NA 0 3 NA ND – VUS: BP4 No Increased risk of 
hypospadias (Carmichael 
et al., 2013), early genital 
primordia (Rey and 
Grinspon, 2011), female 
gonadal development? 
(Jameson et al., 2012)
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6 HOXA13 7:27239079 snv/missense NM_000522.4:c.618C>G:p.
(Phe206Leu)
rs774388075 0.00002 ND 22.3 5 5 NA NA VUS ND – VUS: - No Associated to hypospadias 
(Beleza-Meireles et al., 
2007; van der Zanden et al., 
2012; syndromic, Hand-
foot-genital)/Guttmacher 
syndrome) hypospadias 
(Innis et al., 2002), small 
penis (Goodman et al., 
2000), genital tubercle 
development (Grinspon and 
Rey, 2014)
6 IRX5 16:54965347 deletion/inframe NM_005853.5: 
c.240_242delCTC:p.(Ser81del)
rs1057518726 ND ND – NA NA NA NA NA VUS VUS VUS: PM4: 
nonframeshift 
deletion
No Association to hypospadias 
(Geller et al., 2014; 
Grinspon and Rey, 
2014), female gonadal 
development? (Nef et al., 
2005)
6 IRX6 16:55362842 snv/missense NM_024335.2:c.952T>A:p.
(Phe318Ile)
rs61743419 0.0014 ND 5.599 3 4 0 NA VUS ND – VUS: - No entry for 
this gene
Associated to hypospadias 
(Grinspon and Rey, 2014)
6 MAML1 5:179193168 snv/missense NM_014757.4:c.1157G>T:p.
(Gly386Val)
rs777367230 0.0001 0.003 22.9 9 5 0 NA VUS ND – VUS: - No No (MAMLD1-related)
6 MAML3 4:140811687
NOT 
CONFIRMED
snv/
synonymous
NM_018717.5:c.903C>T:p.
(Asp301=)
rs76066862 0.0015 0.002 2.445 NA NA NA 2 Likely 
benign
ND – VUS: - No Female gonadal 
development? (Jameson 
et al., 2012)
6 NRP1 10:33469272 snv/missense NM_003873.5:c.2504G>A:p.
(Gly835Asp)
– ND ND 5.556 6 4 NA NA VUS ND – VUS: PM2 No DSD (Baxter et al., 2015), 
gonadal development? 
(Jameson et al., 2012)
6 PROP1 5:177421299 deletion/
frameshift
NM_006261.4:c.150delA:p.
(Arg53Aspfs*112)
rs587776683 ND ND – NA NA NA NA NA Pathogenic Likely 
pathogenic
VUS: PVS1, 
PP5
DM; 
pituitary 
hormone 
deficiency
No, hypogonadotropic 
hipogonadism (Reynaud 
et al., 2005; Reynaud et al., 
2005; Baxter and Vilain, 
2013; Baxter et al., 2015; 
Eggers et al., 2016)
6 PTPN11 12:112856827 snv/upstream NM_002834.4:c.-89G>A – ND ND 16.23 NA NA NA NA NA ND – VUS: PM2, 
PP3
No Syndromic (Noonan 
syndrome) cryptorchidism 
(Tartaglia et al., 2002)
6 WDR11 10:122668121 snv/missense NM_018117.11:c.3571G>A:p.
(Gly1191Ser)
rs149486212 0.0001 0.004 34 14 5 NA NA VUS ND – VUS : PP2, 
PP3
No Hypospadias (Eggers et al., 
2016, Fan et al., 2017), 
small testes (Fan et al., 
2017)
7 EVC 4:5800455 snv/missense NM_153717.2:c.2240C>T:p.
(Ala747Val)
rs151091776 0.0002 ND 18.37 5 4 0 NA VUS ND – VUS: BP4 No Syndromic (Ellis–van 
Creveld syndrome) 
hypospadias (D’Asdia et al., 
2013) and micropenis 
(Ibarra-Ramirez et al., 2017), 
gonadal development? 
(Beverdam and Koopman, 
2006; Jameson et al., 2012)
7 MAML3 4:140811709 snv/missense NM_018717.5:c.881A>G:p.
(Asn294Ser)
rs115966590 0.0028 ND 13.26 7 6 NA NA VUS ND – VUS: - No Female gonadal 
development? (Jameson 
et al., 2012)
7 NOTCH2 1:120458982 snv/missense NM_024408.3:c.6363G>C:p.
(Lys2121Asn)
rs144047610 0.0004 0.002 23.4 9 5 NA NA VUS VUS VUS VUS: - DM?, 
Bicuspid 
aortic valve
Primary ovarian failure 
(Patiño et al., 2017); male 
gonadal development? 
(Jameson et al., 2012)
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7 PPARGC1B 5:149219653 snv/missense NM_133263.3:c.2668G>A:p.
(Ala890Thr)
rs150637009 0.0056 ND 19.13 5 5 0 NA VUS ND – VUS: BP4 No Candidate to hypospadias 
(van der Zanden et al., 
2012)
7 WDR11 10:122637900 snv/missense NM_018117.11:c.1592C>G:p.
(Ser531Cys)
rs775506715 0.00004 ND 24.1 14 6 1 NA VUS ND – VUS: PP2, PP3 No Hypospadias (Eggers et al., 
2016, Fan et al., 2017), 
small testes (Fan et al., 
2017)
8 CUL4B X:119708447 snv/missense NM_003588.3:c.26G>A:p.
(Gly9Glu)
rs149016283 0.0002 ND 18.73 1 NA 1 NA Likely 
benign
Likely benign Likely 
benign
Likely benign: 
BP4, BP6
No Abnormal genitourinary 
system (Retterer et al., 
2016)
8 DAPK1 9:90321476 snv/missense NM_004938.3:c.3490G>A:p.
(Asp1164Asn)
rs937952689 0.00007 ND 24.3 8 5 NA NA VUS ND – VUS: - No Female gonadal 
development? (Jameson 
et al., 2012)
8 EMX2 10:119305133 snv/intronic NM_004098.3:c.407-10C >T – 0.000004 ND 9.098 NA NA 1 4 ND ND – VUS: BP4 No 46,XX DSD (Liu et al., 
2015), sex determination 
(Biason-Lauber, 2010; 
Jakob and Lovell-Badge, 
2011; Eggers and Sinclair, 
2012), (female) gonadal 
development (Rey et al., 
2000; Jameson et al., 
2012; Grinspon and Rey, 
2014), (Jameson et al., 
2012); 46,XY DSD (Piard 
et al., 2014)
8 FREM2 13:39454885 insertion/
frameshift
NM_207361.5:c.9472dupC:p.
(Gln3160Thrfs*6)
– ND ND – NA NA NA NA ND ND – Likely 
pathogenic: 
PVS1, PM2
No Syndromic (Fraser 
syndrome) abnormal 
genitalia (De Bernardo et al., 
2015), female gonadal 
development (Jameson 
et al., 2012)
8 IGFBP2 2:217526593 snv/missense NM_000597.3:c.685C>A:p.
(Gln229Lys)
– ND ND 23.7 8 6 0 NA VUS ND – VUS: PM2, 
PP3
No entry for 
this gene
Candidate gene in ovary 
development (Clement 
et al., 2007), female gonadal 
development? (Jameson 
et al., 2012; Munger et al., 
2013).
8 MAML2 11:95826575 snv/missense NM_032427.3:c.620G>A:p.
(Arg207His)
rs191391876 0.0002 ND 24.4 9 5 0 NA VUS ND – VUS: - No No (MAMLD1-related)
8 MAML3 4:140811709 snv/missense NM_018717.5:c.881A>G:p.
(Asn294Ser)
rs115966590 0.0028 0.004 13.26 7 6 NA NA VUS ND – VUS: - No Female gonadal 
development? (Jameson 
et al., 2012)
8 MYO7A 11:76883787 delins/intronic NM_000260:c.1798-7_1798-
6delCCinsAT
– ND ND – NA NA NA NA ND ND – – No Male gonadal development? 
(Jameson et al., 2012; Li 
et al., 2014)
8 MYO7A 11:76883790 delins/
intronic-exonic
NM_000260: c.1798-
4_1801delinsGGCTGCT
– ND ND – NA NA NA NA ND ND – – No Male gonadal development? 
(Jameson et al., 2012; Li 
et al., 2014)
8 NOTCH1 9:139405111 snv/missense NM_017617.5:c.2734C>T:p.
(Arg912Trp)
rs201620358 0.002 ND 31 12 6 0 3 Likely 
benign
VUS VUS VUS: PP3 No Related to SHH and FGF10 
(Grinspon and Rey, 2014)
8 PIK3R3 1:46521570 snv/missense NM_003629.3:c.838G>A:p.
(Asp280Asn)
rs186728731 0.0001 ND 25.5 6 6 0 2 VUS ND – VUS: PP3 No Female gonadal 
development? (Beverdam 
and Koopman, 2006; 
Jameson et al., 2012)
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Among them, only MAML2 has not been related to gonadal or 
genitourinary system development (Table 2).
The following genes showed variants in two patients: CYP1A1 
in patients 1 and 6; EVC in patients 1 (2 variants) and 7; IRX5 in 
patients 5 and 6; MAML1 in patients 4 and 6; MAML2 in patients 
5 and 8; NOTCH2 in patients 5 and 7; RECQL4 in patients 2 and 
3 and WDR11 in patients 6 and 7 (Table 2). In addition, 2 genes 
presented variants in 3 patients: MAML3 (patients 6, 7 and 8) and 
NOTCH1 (patients 1, 4 and 8). Furthermore, RIPK4 presented 
2 variants in patient 1. Finally, BNC2 variant c.1868C>A:p.
(Pro623His) (MAF = 0.002) was detected in 2 patients (patient 
1 and 7) and MAML3 variant c.881A>G:p.(Asn294Ser) (MAF = 
0.0028) in patients 7 and 8 (Table 2).
We performed interactome analysis for the identified DSD 
genes using bioinformatic tools for the analysis of possible gene-
protein interactions. The network comprising all genes identified 
is shown in Figure 1. Overall, a connection was found for 27 of 
the 41 genes. MAMLD1 connects directly to MAML1/2/3. Via 
NOTCH1/2 8 genes are in connection with MAMLD1, namely 
WNT9A/9B, GLI2/3, FGF10, RET, PROP1 and NRP1. Some of 
these genes are also central nodes for further connections; e.g. 
GLI3 for EVC, FGF10, GLI2, RIPK4 and EYA1; and RET for 
PIK3R3 with PTPN11, which also is connected with RIPK4. 
RIPK4 itself is a central node for ZBTB16, CUL4B, GLI3 and 
PTPN11. NRP1 is connected to FLNA and EYA1 connects 
with FRAS1 and FREM2. In addition, 2 isolated gene couples 
have been revealed by our analysis: CYP1A1-HSD3B2 and 
MYO7A-CDH23. These observations give an idea of the complex 
interactions among genes related to sex development.
The specific interactome of identified genes in patients 1 and 
4 to 8 is shown in Figure 2. In patients 1, 4, 5, 7 and 8, MAMLD1 
and MAMLD1-related genes (MAML1, MAML2 or MAML3) are 
directly related to NOTCH1/2 (Figures 2A–C, E, F). In patient 1, 
there are 2 networks: ZBTB16-RIPK4 and MAMLD1-NOTCH1-
RET (Figure 2A). In patient 6, GLI3, EYA1 and FRAS1 as well as 
FLNA and NRP1 seem directly related (Figure 2D). In patient 8, 
NOTCH1 plays a central role connecting to WNT9A, WNT9B 
and MAMLD1 network (Figure 2F).
DISCUSSION
Sex development is a very complex biological event which requires 
the concerted collaboration of a large network of genes in a spatial 
and temporal correct fashion. In the past, much has been learned 
about human sex development from monogenic DSD, but the broad 
spectrum of phenotypes in numerous DSD individuals remains 
a conundrum. Oligogenic disease has been proposed. In fact, 
multiple genetic hits, which might not be deleterious by themselves, 
have been found in several individuals with DSD (Kon et al., 2015; 
Eggers et al., 2016; Mazen et al., 2016; Werner et al., 2017; Camats 
et al., 2018). In a previous study of 46,XY DSD patients carrying 
MAMLD1 variants, we showed that none of the variants were 
functionally pathogenic except for a stop variant (Camats et al., 
2015). In the present study, we searched for additional genetic hits in 
DSD patients harboring MAMLD1 mutations and manifesting with 
unexplained broad phenotypes. Using HTS and a custom-made 
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algorithm including DSD- and MAMLD1-related genes from 
literature and databases, we identified potentially deleterious 
genetic variants in additional genes in all MAMLD1 individuals. 
Thus, we believe that the broad phenotype of individuals carrying 
MAMLD1 variants is due to additional genetic hits.
In our study, we identified 55 additional heterozygous/
hemizygous variants in 41 genes in seven 46,XY DSD hemizygous 
and one 46,XX DSD heterozygous MAMLD1 patients. Among 
the 41 genes, 16 have been previously reported in humans with 
hypospadias (ATF3, BNC2, CYP1A1, EMX2, EYA1, FLNA, 
GLI3, GRID1, GLI2,, FGF10, HOXA13, HSD3B2, IRX5, IRX6, 
PPARGC1B and WDR11 (Table 2); 8 have been related to 
cryptorchidism (BNC2, FLNA, RET, RECQL4, NRP1, PTPN11, 
RIPK4 and ZBTB16), and 5 genes have been found in patients with 
micropenis (BNC2, EVC, FGF10, RIPK4 and ZBTB16). Also, 15 
genes have been described in other types of DSD (CUL4B, EMX2, 
FRAS1, FREM2, HSD3B2, NOTCH2 and NRP1) (Table 2) and/
or were reported in different syndromes (CYP1A1, EVC, FRAS1, 
HOXA13, PTPN11, RECQL4, RET, RIPK4 and ZBTB16) (Table 2). 
In addition, 27 genes had been previously described in the context 
of sex or gonadal development (ATF3, BNC2, CDH23, COL9A3, 
DAPK1, EMX2, EVC, EYA1, FLNA, FRAS1, FREM2, GLI2, GLI3, 
HOXA13, IGFBP2, IRX5, MAML3, MYO7A, NOTCH1, NOTCH2, 
NRP1, PIK3R3, RET, RIPK4, TGFBI, WNT9A and WNT9B). 
Thirteen of these genes have been found involved in female 
gonadal development and 46,XX DSD (ATF3, DAPK1, EMX2, 
FLNA, FRAS1, FREM2, GLI3, IGFBP2, IRX5, MAML3, PIK3R3, 
WNT9A and WNT9B), 8 of which in patient 8 (Table 2).
According to OMIM, almost all of our patients presented at 
least one variant in a gene with autosomal dominant inheritance 
(AD) (COL9A3, GLI2, FGF10, FLNA, EYA1, GLI3, HOXA13, 
NOTCH1, NOTCH2, PTPN11, RET, TGFB and WDR11), while 
other genes (CDH23, MYO7A and PPARGC1B) may have both 
AD and autosomal recessive (AR) inheritance. FLNA and CUL4B 
are X-linked (XLR), while CYP1A1, FREM2, EVC, HSD3B2, IRX5, 
PROP1, RAS1, RECQL4, RIPK4 and ZBTB16 are known for AR 
inheritance. No information on inheritance is currently available 
for the remaining genes including ATF3, BNC2, GRID1, DAPK1, 
IRX6, IGFBP2, MAML1, MAML2, MAML3, NRP1, PIK3R3, 
WNT9A and WNT9B.
The seven MAMLD1 patients with 46,XY DSD presented 
phenotypes from female external genitalia (patient 4) to variable 
degrees of hypospadias, cryptorchidism and small penis (Table 1). 
Interestingly, patient 4 with female external genitalia had normal 
T secretion. Similarly, patient 5 carrying a heterozygous HSD3B2 
variant, had normal levels of 17OH-pregnenolone, DHEA and 
DHEA-S (data not shown). Patient 6, who presented with a right 
aortic arch, was found to carry variants in five genes (BNC2, 
FLNA, MAML1, NRP1 and PTPN11) that have been previously 
described in patients with heart and/or vascular anomalies 
(Tartaglia et al., 2002; Bhoj et al., 2011; Lee et al., 2014; Shaheen 
et  al., 2015; Preuss et al., 2016; Chen et al., 2018). The 46,XX 
patient (patient 8), with primary amenorrhea, hypergonadotropic 
hypogonadism, normal female external genitalia and small 
uterus harbored gene variants involved in gonadal development 
and DSD (CUL4B, DAPK1, EMX2, FREM2, IGFBP2, MAML3, 
MYO7A, NOTCH1, PIK3R3, TGFBI, WNT9A and WNT9B; 
Table 2). Five of these genes (DAPK1, IGFBP2, MAML3, PIK3R3 
and WNT9A) have so far only been related to female gonadal 
development (Table 2).
Overall, the genes detected in our eight studied patients with 
MAMLD1 variants have been previously reported in humans 
with hypospadias, cryptorchidism, micropenis, and other 
urogenital abnormalities; or they have been found involved in 
sexual and gonadal development. Also, some of them have been 
associated with specific syndromes in patients with genitourinary 
anomalies: CAKUT syndrome, Ellis–van Creveld syndrome, 
Fraser syndrome 1, Fraser syndrome 2, hand–foot–genital/
Guttmacher syndrome, Noonan syndrome, Mayer–Rokitansky–
Küster–Hauser syndrome, Popliteal pterygium syndrome and 
Rothmund–Thomson syndrome (see Table 2). However, none of 
the present patients presented a complete phenotype for any of 
these syndromes, maybe because none of the variants completely 
impairs gene expression and protein function, as inferred by 
the in silico analyses. Detailed information on these genes from 
current literature is given in Supplementary Materials (S1).
A search for an underlying network comprising variants in the 
identified genes related to MAMLD1 revealed a considerable number 
of genes which showed gene-gene, gene-protein or protein-protein 
interactions (Figures 1 and 2) suggesting that genetic variations in 
these genes may affect sex development. In addition, MAML3 was 
found in a network related to female gonadal development (Jameson 
et al., 2012). Accordingly, one variant in MAML3 was present in our 
46,XX patient. The analysis of gene/protein network interactions 
per patient gives an idea of the complexity of the interactions among 
genes related to sex development. The more variants detected 
in DSD-related genes, the better to build an interaction network 
searching for clues on genetic relationship(s) for sex development. 
In our DSD individuals carrying MAMLD1 variants, three genes 
seemed prominent in the network analysis, NOTCH1, NOTCH2 
and GLI3. NOTCH signaling is a highly conserved signaling 
pathway and comprises 4 transmembrane receptors. It is essential 
for the regulation of embryonic development of multiple organ 
systems including gonadal development (Windley and Wilhelm, 
2016). NOTCH signaling is implicated in Leydig cell differentiation 
in an inhibitory regulatory fashion (Windley and Wilhelm, 2016). 
Autosomal dominant mutations in NOTCH1 cause the Adams–
Oliver syndrome (OMIM 616028), while autosomal dominant 
mutations in NOTCH2 are reported in the Alagille syndrome 2 
(OMIM 610205) and in the Hajdu–Cheney syndrome (OMIM 
102500). By contrast, GLI3 is a zinc-finger transcription factor 
belonging to the desert hedgehog (DHH) signal transduction 
pathway. DHH signaling is essential for driving Leydig cell 
differentiation (Windley and Wilhelm, 2016). Thus, NOTCH and 
DHH signaling work together to regulate Leydig cell development 
(Windley and Wilhelm, 2016). Autosomal dominant mutations in 
GLI3 are described in the Pallister–Hall syndrome (OMIM 146510) 
or in the Greig cephalopolysyndactyly syndrome (OMIM 175700).
Taken together, our results expand the landscape of genes 
possibly involved in DSD by revealing both new and old players. 
Genetic platforms for DSD diagnostics currently consider about 
270 genes that have been identified with monogenetic forms of 
DSD in (mostly) several independent individuals (Cools et al., 
2018). Our eight MAMLD1 individuals share variants in 19 genes 
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comprised in such DSD panels, including ATF3, BNC2, CUL4B, 
EVC, FLNA, FRAS1, FREM2, GLI3, HOXA13, HSD3B2, IRX5, 
NOTCH2, PROP1, PTPN11, RECQL4, RET, RIPK4, WDR11 and 
ZBTB16. By contrast, through our work 22 new genes are now 
added for considering with differences in sex development: CDH23, 
COL9A3, CYP1A1, DAPK1, EMX2, EYA1, FGF10, GLI2, GRID1, 
IGFBP2, IRX6, MAML1, MAML2, MAML3, MYO7A, NOTCH1, 
NRP1, PIK3R3, PPARGC1B, TGFBI, WNT9A and WNT9B.
Ideally, genetic variants are tested functionally for proof of 
their disease-causing effect in model systems. However, when 
finding multiple variants, which may all contribute only partially, 
such testing is no longer feasible. Therefore, the likelihood of 
disease-causing effect of identified variants was assessed in our 
study by established bioinformatic tools for genetics and by 
assessing the genotype-phenotype correlation in each patient 
with current knowledge from literature and databases in the 
field. In future studies with bigger sample size, next-generation 
statistical genetic analyses may be employed to identify 
associations between a group of variants and the complex trait of 
sex development (Weissenkampen et al., 2019).
In summary, HTS analysis indicates that the broad DSD 
phenotypes of MAMLD1 patients may be due to additional 
variants in other DSD-related genes. We found up to 55 additional 
genetic hits that may contribute to the DSD phenotype making 
an oligogenic causation plausible. Bioinformatic network analysis 
can help in interpreting complex genetic data and put identified 
single candidate genes into a greater perspective to understand 
their possible role in DSD biology.
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